Free tool
FAERS Monitor: Nitrogen, Nf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217499 or its brand name (Nitrogen, Nf, Nitrogen). Reports on generic versions are filed under their own applications.
Reports
110
Serious
93
85% of reports
Hospitalization
33
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use10
- malaise9
- drug interaction7
- accidental exposure to product6
- psoriasis6
- completed suicide5
- dyspnoea5
- haemodynamic instability5
- product leakage5
- ventricular fibrillation5
- weight decreased5
- death4
- dry gangrene4
- extremity necrosis4
- injection site reaction4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 13 |
| 2018 | 15 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 10 |
| 2025 | 4 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,049 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dry gangreneSignal | 4 | 1213.3 | 462.2 | 3,686 |
| extremity necrosisSignal | 4 | 439.5 | 167.7 | 1,336 |
| product leakageSignal | 5 | 170.5 | 72.4 | 681 |
| haemodynamic instabilitySignal | 5 | 125.6 | 53.3 | 499 |
| ventricular fibrillationSignal | 5 | 86.1 | 36.6 | 340 |
| completed suicideSignal | 5 | 11.5 | 4.9 | 38 |
| accidental exposure to productSignal | 6 | 11.1 | 5.1 | 46 |
| injection site reactionSignal | 4 | 11.1 | 4.2 | 27 |
| psoriasisSignal | 6 | 8.8 | 4.0 | 34 |
| drug interactionSignal | 7 | 8.4 | 4.1 | 39 |
| malaiseSignal | 9 | 3.9 | 2.1 | 17 |
| weight decreasedSignal | 5 | 3.4 | 1.5 | 6 |
| off label useSignal | 10 | 2.2 | 1.2 | 6 |
| dyspnoea | 5 | 1.7 | 0.7 | 1 |
| death | 4 | 0.9 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.